DECIBEL CANNABIS COMPANY INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.11 CAD | -4.35% |
|
-8.33% | -15.38% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The stock, which is currently worth 2024 to 0.72 times its sales, is clearly overvalued in comparison with peers.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -15.38% | 33.07M | - | ||
| +42.38% | 6.26B | B- | ||
| -15.86% | 4.49B | C+ | ||
| +6.36% | 3.29B | C | ||
| -11.28% | 3.12B | B- | ||
| -3.23% | 2.5B | - | D+ | |
| +45.24% | 1.94B | - | ||
| -7.89% | 1.68B | - | - | |
| -0.98% | 1.63B | - | - | |
| -11.32% | 1.56B | C- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
- Stock Market
- Equities
- DB Stock
- Ratings Decibel Cannabis Company Inc.
